କାର୍ବେଟୋସିନ

କାର୍ବେଟୋସିନ
Clinical data
Trade names	Duratocin, Pabal, Lonactene, others
Synonyms	(2-O-Methyltyrosine)deamino-1-carbaoxytocin; Deamino-2-O-methyltyrosine-1-carbaoxytocin; 1-Butanoic acid-2-(O-methy-L-tyrosine)-1-carbaoxytocin; 1-butyric acid-2-[3-(4-methoxyphenyl)-L-alanine]oxytocin
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	Intravenous, intramuscular
ATC code	H01BB03 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only) ; US: Not available;
Pharmacokinetic data
Bioavailability	80% (IM)
Elimination half-life	85–100 minutes
Identifiers
	IUPAC name (2S)-1-[(3S,6S,9S,12S,15S)-12-[(2S)-butan-2-yl]-; 9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-; [(4-hydroxyphenyl)methyl]-16-methyl-5,8,11,14,17-; pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-; 3-carbonyl]-N-[(1S)-1-(carbamoylmethylcarbamoyl)-; 3-methyl-butyl]pyrrolidine-2-carboxamide;
CAS Number	37025-55-1 ;
PubChem CID	16681432;
DrugBank	DB01282 ;
ChemSpider	16736854 ;
UNII	88TWF8015Y;
KEGG	D07229 ;
ECHA InfoCard	100.048.450
Chemical and physical data
Formula	C45H69N11O12S
Molar mass	୯୮୮.୧୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)Cc2ccc(cc2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;
	InChI InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1 ; Key:NSTRIRCPWQHTIA-DTRKZRJBSA-N ;
(what is this?) (verify)

କାର୍ବେଟୋସିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବ୍ୟବସାୟୀକ ନାମ ପାବଲ, ଏକ ଔଷଧ ଯାହାକି ପ୍ରସବପର ଅତ୍ୟଧିକ ରକ୍ତସ୍ରାବ, ବିଶେଷତଃ ସିଜରିଆନ ସେକସନ ଅପରେଶନ ପରେ ହେଉଥିବା ରକ୍ତସ୍ରାବକୁ ରୋକିବା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ, । ^[୨] ଏହା ଅକ୍ସିଟୋସିନ୍ ଭଳି କାମ କରୁଥିବା ପରି ଜଣାଯାଏ | ^[୩] ଅନ୍ୟ ବିକଳ୍ପ ତୁଳନାରେ ଏହାର ଅଧିକ ଦାମ ରହୁଥିବାରୁ ଏନଏଚଏସ ସ୍କଟଲ୍ୟାଣ୍ଡ ଏହାକୁ ବ୍ୟବହାର କରିବାକୁ ସୁପାରିଶ କରେନି | ^[୪] ଏହା ଶିରା କିମ୍ବା ମାଂସପେଶୀରେ ଇଞ୍ଜେକନ ଆକାରରେ ଦିଆଯାଏ | ^[୫]

ଆଦୌ ଚିକିତ୍ସା ନ କଲେ ବା କୌଣସି ବିଶେଷ ଚିକିତ୍ସା କିମ୍ବା ପ୍ଲାସେବୋଠାରୁ ଭିନ୍ନ କିଛି ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ଦେଖାଯାଏ ନାହିଁ |^[୩] ଅପସ୍ମାର କିମ୍ବା ଏକ୍ଲାମ୍ପସିଆ ରୋଗୀଙ୍କଠାରେ ଏହା ବ୍ୟବହାର କରିବାକୁ ସୁପାରିଶ କରାଯାଏ ନାହିଁ। ^[୨] ଅକ୍ସିଟୋସିନର ଏକ ଦୀର୍ଘ କାର୍ଯ୍ୟକାରୀ ଆକାର ରୂପେ କାର୍ବେଟୋସିନ ନିର୍ମିତ | ^[୫] ଏହା ଅକ୍ସିଟୋସିନ ରିସେପ୍ଟରକୁ ସକ୍ରିୟ କରିବାଦ୍ୱାର ଜରାୟୁର ସଙ୍କୋଚନ ବୃଦ୍ଧି ପାଇଥାଏ | ^[୬] ^[୫]

୧୯୭୪ ମସିହାରେ କାର୍ବେଟୋସିନ ବିଷୟ ପ୍ରଥମେ ବର୍ଣ୍ଣନା କରାଯାଇଥିଲା |^[୭] କାନାଡା ଏବଂ ଯୁକ୍ତରାଜ୍ୟରେ ୧୯୯୭ ମସିହାରେ ଚିକିତ୍ସା ପାଇଁ ଏହାର ବ୍ୟବ‌ହାରକୁ ଅନୁମୋଦିତ ହୋଇଥିଲା । ^[୩] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ତାଲିକାର ଅଛି । ^[୮] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୧୮ ସୁଦ୍ଧା ଏନଏଚଏସକୁ ଏହା ନିମନ୍ତେ ୧୮ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ କରିବାକୁ ପଡ଼ୁଛି | ^[୨] ଭୂମଣ୍ଡଳ ସ୍ତରରେ ଏହାର ମୂଲ୍ୟ 8ରୁ 40 ପାଉଣ୍ଡ ମଧ୍ୟରେ ଥାଏ | ^[୫] ଏହା ଆମେରିକା କିମ୍ବା ଜାପାନରେ ଉପଲବ୍ଧ ନୁହେଁ | ^[୯] ^[୫]

ଆଧାର

↑ Idan Shalev; Richard Paul Ebstein (11 February 2015). Social Hormones and Human Behavior: What Do We Know and Where Do We Go from Here. Frontiers Media SA. pp. 51–. ISBN 978-2-88919-407-0.
↑ ^୨.୦ ^୨.୧ ^୨.୨ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 804. ISBN 9780857113382.
↑ ^୩.୦ ^୩.୧ ^୩.୨ "PROPOSAL FOR INCLUSION OF CARBETOCIN IN THE WHO LIST OF ESSENTIAL MEDICINES" (PDF). WHO. Retrieved 12 November 2019.
↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 804. ISBN 9780857113382.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "PROPOSAL FOR INCLUSION OF CARBETOCIN IN THE WHO LIST OF ESSENTIAL MEDICINES" (PDF). WHO. Retrieved 12 November 2019.
↑ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 65–. ISBN 978-94-011-4439-1.
↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 214–. ISBN 978-1-4757-2085-3.
↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
↑ "Carbetocin Drug Information, Professional". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 November 2020. Retrieved 26 December 2020.

[ShalevEbstein2015-1] Idan Shalev; Richard Paul Ebstein (11 February 2015). Social Hormones and Human Behavior: What Do We Know and Where Do We Go from Here. Frontiers Media SA. pp. 51–. ISBN 978-2-88919-407-0.

[BNF76-2] ୨.୦ ^୨.୧ ^୨.୨ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 804. ISBN 9780857113382.

[WHO2019Inclu-3] ୩.୦ ^୩.୧ ^୩.୨ "PROPOSAL FOR INCLUSION OF CARBETOCIN IN THE WHO LIST OF ESSENTIAL MEDICINES" (PDF). WHO. Retrieved 12 November 2019.

[autogen4-4] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 804. ISBN 9780857113382.

[autogen2-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "PROPOSAL FOR INCLUSION OF CARBETOCIN IN THE WHO LIST OF ESSENTIAL MEDICINES" (PDF). WHO. Retrieved 12 November 2019.

[Morton2012-6] I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 65–. ISBN 978-94-011-4439-1.

[Elks2014-7] J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 214–. ISBN 978-1-4757-2085-3.

[WHO21st-8] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[MMX2020-9] "Carbetocin Drug Information, Professional". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 November 2020. Retrieved 26 December 2020.

[୨]

[୩]

[୪]

[୫]

[୧]

[୬]

[୭]

[୮]

[୯]